23andMe files for bankruptcy protection

The 23ndme DNA test company submitted a request for bankruptcy, and announced that the co -founder and CEO, Ann Wujiki, resigned from an immediate impact.

The company will now try to sell itself under the supervision of the court.

23andme He said in a press release He plans to continue working during the sale and that “there are no changes in the way that the company is stored, managed or protects customer data.”

On Friday, the California Employee’s General Prosecutor in the state of California, who advises customers to delete their data from the site in view of the “financial distress reported to the company.

The 23ndme test programs based on saliva were celebrated between customers and investors, who helped pay the company’s value to 6 billion dollars (4.6 billion pounds).

But it was Struggle to stay.

The company was founded in 2006, and the company became public in 2021, but it has never made a profit.

In September, the company settled a lawsuit claiming to have failed to protect the privacy of nearly seven million customers whose personal information was revealed in a 2023 data breach.

In some cases, infiltrators were able to reach family trees, birth years and geographical sites, using old passwords for customers. The stolen data did not include DNA records, according to the company.

After two months of settlement, Cut 200 employeesIt reaches 40 % of the workforce.

The financing chief, Joe Silsavag, will take over the position of temporary CEO.

Mrs. WoJCICKI will continue to work as a member of the Board of Directors.

I tried to take the private company, but it was not open to receive a third party.

23andme – which was once a high -level approval such as Opera Winfrey, Eva Longoria and Snooop Dogg – struggled to redefine her business model.

Customers did not have a lot to return once who had paid for the DNA report, and it has proven an attempt to launch a subscription service that it was unsuccessful.

The efforts made to use the huge data set to move to the development of the drug.

All the managers of the company, with the exception of Mrs. Wogiki to resign Last summer, saying in a speech they were resigning after not receiving a patient’s purchase offer from them.